Procymidone

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:10188193	IVR	100 mg/kg/day	100 mg/kg/day	Changes in white blood cell (WBC) populations	Immunological endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Alteration in prostate morphology	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects testicular morphology	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects anogenital distance	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased weights of accessory sex organs	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Nipple retention	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Changes in morphology of seminal vesicles	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Affects anogenital distance	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Changes in white blood cell (WBC) populations	Immunological endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Changes in white blood cell (WBC) populations	Immunological endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Nipple retention	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Nipple retention	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Affects testicular morphology	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Alteration in prostate morphology	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Decreased weights of accessory sex organs	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Decreased weights of accessory sex organs	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Testicular atrophy	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Changes in morphology of seminal vesicles	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Affects anogenital distance	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Changes in morphology of seminal vesicles	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Alteration in prostate morphology	Reproductive endocrine-mediated perturbations
	IVR	200 mg/kg/day	200 mg/kg/day	Hyperplasia in ovary	Reproductive endocrine-mediated perturbations
	IVR	25 mg/kg/day	25 mg/kg/day	Decreased weights of accessory sex organs	Reproduct
	IVR	25 mg/kg/day	25 mg/kg/day	Affects anogenital distance
	IVR	25 mg/kg/day	25 mg/kg/day	Changes in morphology of seminal vesicles
	IVR	25 mg/kg/day	25 mg/kg/day	Nipple retention
	IVR	25 mg/kg/day	25 mg/kg/day	Alteration in prostate morphology
PMID:10188194	IVR	100 mg/kg/day	100 mg/kg/day	Nipple retention	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Changes in mammary gland morphology	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects anogenital distance	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Changes in morphology of accessory sex organs	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects vaginal development	Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
PMID:15013065	IVR	10 mg/kg/day	10 mg/kg/day	Decreased LH levels	Reproductive endocrine-mediated perturbations
	IVR	3 mg/kg/day	-	No significant effects observed	-
	IVR	100 mg/kg/day	100 mg/kg/day	Increased prostate weights	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased weights of seminal vesicles	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Increased weights of bulbocavernosus muscles/LABC	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased LH levels	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Increased cowper's gland weights	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased weights of adrenal gland	Metabolic endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Increased prostate weights	Reproductive endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Decreased weights of seminal vesicles	Reproductive endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Decreased LH levels	Reproductive endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.